EPAS1 and cancer: Furthermore, these results indicated that HIF-1α and HIF-2α are viable targets, alone or in conjunction with anti-angiogenic (anti-VEGF-A or anti-EphA2 drug) cancer therapies, for the treatment of patients with HCC after HIFU ablation.